Innate Pharma annual depreciation and amortization
2017
2018
2019
2020
2021
2022
2023
2024
2025
Innate Pharma Depreciation & Amortization Growth & History (IPH)
Innate Pharma's depreciation and amortization was €1.4M for fiscal 2025.
View full Innate Pharma company overviewInnate Pharma annual depreciation and amortization history
| Fiscal year | Period ended | Depreciation and amortization | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | €1.4M | −€604,000 | −30.38% |
| 2024 | 2024-12-31 | €2.0M | −€3.1M | −60.97% |
| 2023 | 2023-12-31 | €5.1M | −€40.3M | −88.78% |
| 2022 | 2022-12-31 | €45.4M | €40.8M | +887.92% |
| 2021 | 2021-12-31 | €4.6M | −€52.2M | −91.91% |
| 2020 | 2020-12-31 | €56.8M | €40.3M | +243.62% |
| 2019 | 2019-12-31 | €16.5M | €9.1M | +123.30% |
| 2018 | 2018-12-31 | €7.4M | €3.0M | +68.38% |
| 2017 | 2017-12-31 | €4.4M | — | — |
Innate Pharma depreciation and amortization trends
Over the last five fiscal years, Innate Pharma's depreciation and amortization decreased from €56.8M to €1.4M, a change of −€55.4M.
About the metric
What depreciation and amortization mean
Depreciation and amortization allocate the cost of tangible and intangible assets over their useful lives. These non-cash expenses reduce reported earnings and are commonly added back when calculating EBITDA and operating cash flow.
Calculation and source
Reported depreciation and amortization
TickerStat uses a combined depreciation and amortization value when reported. If a company reports the two components separately for an aligned period, they are added together without duplicating overlapping facts. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Innate Pharma source filings ↗